These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
333 related items for PubMed ID: 34289757
1. Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes. Mastroianni G, Ascoli M, Gasparini S, Brigo F, Cianci V, Neri S, Russo E, Aguglia U, Ferlazzo E. Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1427-1433. PubMed ID: 34289757 [Abstract] [Full Text] [Related]
2. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Gericke CA, Picard F, de Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Epileptic Disord; 1999 Sep; 1(3):159-65. PubMed ID: 10937148 [Abstract] [Full Text] [Related]
3. Treatment of typical absence seizures and related epileptic syndromes. Panayiotopoulos CP. Paediatr Drugs; 2001 Sep; 3(5):379-403. PubMed ID: 11393330 [Abstract] [Full Text] [Related]
4. [Use of lamotrigine in the treatment of absence epilepsy crises]. Mauri-Llerda JA, Tejero-Juste C, Iñiguez C, Morales-Asín F. Rev Neurol; 2001 Sep; 32(3):247-50. PubMed ID: 11310280 [Abstract] [Full Text] [Related]
6. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Brigo F, Igwe SC. Cochrane Database Syst Rev; 2017 Feb 14; 2(2):CD003032. PubMed ID: 28195639 [Abstract] [Full Text] [Related]
7. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas Park E, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J. Neurology; 2018 Jul 10; 91(2):74-81. PubMed ID: 29898971 [Abstract] [Full Text] [Related]
8. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy. Ascoli M, Mastroianni G, Gasparini S, Striano P, Cianci V, Neri S, Bova V, Mammì A, Gambardella A, Labate A, Aguglia U, Ferlazzo E. Expert Rev Neurother; 2021 Nov 10; 21(11):1265-1273. PubMed ID: 33993822 [Abstract] [Full Text] [Related]
9. The management of refractory idiopathic epilepsies. Perucca E. Epilepsia; 2001 Nov 10; 42 Suppl 3():31-5. PubMed ID: 11520320 [Abstract] [Full Text] [Related]
10. Lamotrigine in typical absence epilepsy. Buoni S, Grosso S, Fois A. Brain Dev; 1999 Jul 10; 21(5):303-6. PubMed ID: 10413016 [Abstract] [Full Text] [Related]
11. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. Chu H, Zhang X, Shi J, Zhou Z, Yang X. J Neurol; 2023 Oct 10; 270(10):4713-4728. PubMed ID: 37378757 [Abstract] [Full Text] [Related]
12. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Brigo F, Igwe SC, Lattanzi S. Cochrane Database Syst Rev; 2019 Feb 08; 2(2):CD003032. PubMed ID: 30734919 [Abstract] [Full Text] [Related]
13. Low-dose phenobarbital for epilepsy with myoclonic absences: A case report. Ito S, Nagumo K, Nishikawa A, Oguni H, Nagata S. Brain Dev; 2021 May 08; 43(5):666-668. PubMed ID: 33461850 [Abstract] [Full Text] [Related]
14. Latencies to first typical generalized spike-wave discharge in idiopathic generalized epilepsies during video-EEG monitoring. Oehl B, Götz-Trabert K, Brandt A, Lehmann C, Schulze-Bonhage A. J Clin Neurophysiol; 2010 Feb 08; 27(1):1-6. PubMed ID: 20087210 [Abstract] [Full Text] [Related]
15. Lamotrigine in absence and primary generalized epilepsies. Mikati MA, Holmes GL. J Child Neurol; 1997 Nov 08; 12 Suppl 1():S29-37. PubMed ID: 9429128 [Abstract] [Full Text] [Related]